BR112017020408A2 - ?biotinas e composições? - Google Patents

?biotinas e composições?

Info

Publication number
BR112017020408A2
BR112017020408A2 BR112017020408A BR112017020408A BR112017020408A2 BR 112017020408 A2 BR112017020408 A2 BR 112017020408A2 BR 112017020408 A BR112017020408 A BR 112017020408A BR 112017020408 A BR112017020408 A BR 112017020408A BR 112017020408 A2 BR112017020408 A2 BR 112017020408A2
Authority
BR
Brazil
Prior art keywords
biotins
compositions
nmo
biotin
treatment
Prior art date
Application number
BR112017020408A
Other languages
English (en)
Inventor
Sedel Frédéric
Original Assignee
Medday Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52779582&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017020408(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medday Pharmaceuticals filed Critical Medday Pharmaceuticals
Publication of BR112017020408A2 publication Critical patent/BR112017020408A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

a presente invenção refere-se ao uso de biotina para o tratamento de esclerose lateral amiotrófica, bem como neuropatias periféricas desmielinizantes e neuromielite óptica (nmo).
BR112017020408A 2015-03-26 2016-03-25 ?biotinas e composições? BR112017020408A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305437.4A EP3072513A1 (en) 2015-03-26 2015-03-26 Biotin for treating Amyotrophic lateral sclerosis
PCT/EP2016/056696 WO2016151132A1 (en) 2015-03-26 2016-03-25 Biotin for treating amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
BR112017020408A2 true BR112017020408A2 (pt) 2018-06-05

Family

ID=52779582

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020408A BR112017020408A2 (pt) 2015-03-26 2016-03-25 ?biotinas e composições?

Country Status (23)

Country Link
US (2) US10357480B2 (pt)
EP (2) EP3072513A1 (pt)
JP (1) JP6752874B2 (pt)
KR (1) KR20170131543A (pt)
CN (2) CN107405335A (pt)
AU (1) AU2016238759B2 (pt)
BR (1) BR112017020408A2 (pt)
CA (1) CA2980660A1 (pt)
CY (1) CY1122374T1 (pt)
DK (1) DK3273957T3 (pt)
EA (1) EA034394B1 (pt)
ES (1) ES2748354T3 (pt)
HR (1) HRP20191491T1 (pt)
HU (1) HUE046116T2 (pt)
IL (1) IL254619B (pt)
LT (1) LT3273957T (pt)
MA (1) MA41809B1 (pt)
ME (1) ME03567B (pt)
PL (1) PL3273957T3 (pt)
PT (1) PT3273957T (pt)
RS (1) RS59149B1 (pt)
SI (1) SI3273957T1 (pt)
WO (1) WO2016151132A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
EP3275439A1 (en) 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
CN112386703A (zh) * 2020-01-15 2021-02-23 李启芳 治疗als的联合用药物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885976A (en) * 1995-05-08 1999-03-23 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
RS20050255A (en) 2002-09-27 2007-08-03 Biogen Idec Ma Inc., Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-betha
US20050249823A1 (en) * 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
FR2905868B1 (fr) * 2006-09-18 2012-12-21 Gemac Composition destinee au traitement de la sclerose laterale amyotrophique
WO2011077239A2 (en) 2009-12-23 2011-06-30 Lupin Limited Slow release pharmaceutical compositions of iloperidone
FR2958166B1 (fr) 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
FR2993780B1 (fr) * 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
KR20140059168A (ko) * 2011-04-21 2014-05-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 시신경 척수염 치료용 조성물 및 치료 방법
JP6145946B2 (ja) * 2011-07-13 2017-06-14 サイトキネティックス， インコーポレイテッド 併用ａｌｓ療法
WO2014177286A1 (en) 2013-04-29 2014-11-06 Assistance Publique - Hopitaux De Paris Biotin for use in treating x-linked adrenoleukodystrophy
JP6664956B2 (ja) * 2015-02-27 2020-03-13 キリンホールディングス株式会社 筋分化促進組成物
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
RS59149B1 (sr) 2019-09-30
EA034394B1 (ru) 2020-02-04
HRP20191491T1 (hr) 2019-11-15
MA41809A (fr) 2018-01-30
US20190314342A1 (en) 2019-10-17
MA41809B1 (fr) 2019-12-31
US10357480B2 (en) 2019-07-23
LT3273957T (lt) 2019-11-11
PT3273957T (pt) 2019-09-18
AU2016238759A1 (en) 2017-10-05
ME03567B (me) 2020-07-20
US20180125825A1 (en) 2018-05-10
JP2018512451A (ja) 2018-05-17
ES2748354T3 (es) 2020-03-16
CY1122374T1 (el) 2021-01-27
EP3273957A1 (en) 2018-01-31
EP3072513A1 (en) 2016-09-28
CN107405335A (zh) 2017-11-28
IL254619B (en) 2020-03-31
CA2980660A1 (en) 2016-09-29
WO2016151132A1 (en) 2016-09-29
EP3273957B1 (en) 2019-08-14
NZ735528A (en) 2021-09-24
JP6752874B2 (ja) 2020-09-09
DK3273957T3 (da) 2019-11-11
EA201792124A1 (ru) 2018-04-30
CN111973592A (zh) 2020-11-24
PL3273957T3 (pl) 2020-01-31
SI3273957T1 (sl) 2019-11-29
KR20170131543A (ko) 2017-11-29
AU2016238759B2 (en) 2020-08-06
HUE046116T2 (hu) 2020-02-28
IL254619A0 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
BR112018006471A2 (pt) compostos úteis como moduladores de trpm8
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
BR112018010118A2 (pt) inibidores de cxcr2
BR112016023558A2 (pt) compostos úteis como imunomoduladores
EA201692219A1 (ru) Способы получения противовирусных соединений
BR112016002391A2 (pt) composições tópicas e métodos de uso das mesmas
BR112016025427A2 (pt) processos de preparação de um inibidor de jak1 e formas do mesmo
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
BR112018011526A2 (pt) compostos policíclicos como inibidores da tirosina quinase de bruton
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112017000730A2 (pt) derivados de pirrolidinona como inibidores de metap-2
BR112017008481A2 (pt) composto antimicótico
BR112017018834A2 (pt) variantes de protoxina-ii e métodos de uso
MY186907A (en) Hair growth agent
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
NZ730092A (en) Use of cysteamine in treating infections caused by yeasts/moulds
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
BR112017020896A2 (pt) variantes de protoxina-ii e métodos de uso
CR20160448A (es) Nuevos derivados de piridina
CY1122374T1 (el) Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]